Clinical Trial Update: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating 225Ac-DOTA-Anti-CD38 (daratumumab radiolabeled with Actinium-225) in combination with fludarabine, melphalan, and total marrow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• 225Ac-DOTA-Anti-CD38 monoclonal antibody (daratumumab radiolabeled with Actinium-225) (daratumumab radiolabeled with Actinium-225 DOTA conjugate)
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING